Longitudinal changes in white matter hyperintensity volume accelerate across the Alzheimer's continuum in adults with Down syndrome
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.White matter hyperintensity (WMH) accelerates in adults with Down syndrome (DS) and Alzheimer's disease (AD). Posterior WMH increases most rapidly in individuals progressing from mild cognitive impairment to AD.
Area Of Science
- Neurology
- Neuroimaging
- Down Syndrome Research
Background
- Cerebrovascular disease is common in adults with Down syndrome (DS) throughout the Alzheimer's disease (AD) continuum.
- Regional changes in cerebrovascular disease within individuals with DS are not well understood.
Purpose Of The Study
- To investigate the longitudinal changes in white matter hyperintensity (WMH) volume in adults with DS.
- To determine if WMH progression differs across cognitive states and AD progression.
Main Methods
- Utilized MRI scans from 187 participants in the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study.
- Quantified white matter hyperintensity (WMH) volume and assessed annualized changes.
- Categorized participants into cognitive groups: cognitively stable (CS), mild cognitive impairment (MCI)-DS, and AD, tracking progression or stability.
Main Results
- WMH volume changed over time, decreasing in the cognitively stable group and increasing in advanced AD groups.
- Faster WMH changes, particularly in posterior regions, were observed in individuals with more advanced cognitive decline (MCI-DS to AD, AD).
- A monotonic increase in WMH across progressive diagnostic groups suggests accelerating WMH over time.
Conclusions
- Posterior white matter hyperintensity (WMH) accelerates with Alzheimer's disease (AD) progression in adults with Down syndrome (DS).
- This acceleration is evident starting at the stage of progression from mild cognitive impairment (MCI)-DS to AD.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...